Crinetics Capital Surpluse vs Long Term Debt Analysis

CRNX Stock

USD 60.01 0.68 1.12%

Crinetics Pharmaceuticals financial indicator trend analysis is way more than just evaluating Crinetics Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Crinetics Pharmaceuticals is a good investment. Please check the relationship between Crinetics Pharmaceuticals Capital Surpluse and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Capital Surpluse vs Long Term Debt

Capital Surpluse vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Crinetics Pharmaceuticals Capital Surpluse account and Long Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Crinetics Pharmaceuticals' Capital Surpluse and Long Term Debt is -0.49. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Crinetics Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Crinetics Pharmaceuticals' Capital Surpluse and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Crinetics Pharmaceuticals are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Capital Surpluse i.e., Crinetics Pharmaceuticals' Capital Surpluse and Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.49

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capital Surpluse

Long Term Debt

Long-term debt is a debt that Crinetics Pharmaceuticals has held for over one year. Long-term debt appears on Crinetics Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Crinetics Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Crinetics Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Crinetics Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.Selling General Administrative is likely to rise to about 61 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 188.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	157K	4.3M	13.4M	14.1M
Net Interest Income	157K	4.3M	13.4M	14.1M

Interest Income Net Interest Income

Crinetics Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.87	0.97	0.99	0.5	0.88	0.95	0.9	-0.17	-0.98	0.77	0.52	0.91	0.91	0.17	-0.81	1.0	0.95	0.88	0.84	-0.81	0.56	0.83	0.88	0.66	-0.92
Short Long Term Debt Total	0.87		0.92	0.89	0.85	0.81	0.69	1.0	0.2	-0.85	0.43	0.2	1.0	0.98	-0.16	-0.94	0.85	0.98	0.64	0.59	-0.94	0.85	0.58	0.7	0.43	-0.63
Other Current Liab	0.97	0.92		0.99	0.6	0.95	0.88	0.94	0.06	-0.98	0.63	0.31	0.94	0.92	0.09	-0.86	0.96	0.97	0.8	0.8	-0.86	0.68	0.73	0.86	0.65	-0.85
Total Current Liabilities	0.99	0.89	0.99		0.53	0.92	0.92	0.91	-0.03	-0.99	0.72	0.39	0.92	0.89	0.16	-0.83	0.98	0.96	0.86	0.85	-0.83	0.62	0.79	0.88	0.7	-0.9
Total Stockholder Equity	0.5	0.85	0.6	0.53		0.5	0.24	0.83	0.48	-0.47	-0.06	-0.14	0.81	0.81	-0.53	-0.83	0.47	0.73	0.19	0.14	-0.83	0.91	0.14	0.34	0.0	-0.14
Other Liab	0.88	0.81	0.95	0.92	0.5		0.8	0.82	0.21	-0.89	0.5	0.11	0.83	0.8	0.11	-0.76	0.87	0.87	0.66	0.73	-0.76	0.6	0.68	0.78	0.64	-0.79
Net Tangible Assets	0.95	0.69	0.88	0.92	0.24	0.8		0.73	-0.39	-0.93	0.89	0.67	0.74	0.76	0.36	-0.63	0.97	0.82	0.93	0.88	-0.63	0.29	0.92	0.85	0.72	-0.98
Property Plant And Equipment Net	0.9	1.0	0.94	0.91	0.83	0.82	0.73		0.17	-0.88	0.47	0.22	1.0	0.98	-0.13	-0.94	0.88	0.99	0.68	0.63	-0.94	0.83	0.61	0.73	0.48	-0.67
Net Debt	-0.17	0.2	0.06	-0.03	0.48	0.21	-0.39	0.17		0.09	-0.6	-0.92	0.16	0.05	-0.42	-0.23	-0.2	0.07	-0.4	-0.27	-0.23	0.51	-0.41	-0.2	-0.1	0.37
Retained Earnings	-0.98	-0.85	-0.98	-0.99	-0.47	-0.89	-0.93	-0.88	0.09		-0.76	-0.43	-0.89	-0.86	-0.2	0.78	-0.98	-0.93	-0.89	-0.9	0.78	-0.59	-0.77	-0.9	-0.72	0.93
Accounts Payable	0.77	0.43	0.63	0.72	-0.06	0.5	0.89	0.47	-0.6	-0.76		0.77	0.49	0.48	0.55	-0.32	0.79	0.58	0.94	0.88	-0.32	0.0	0.88	0.68	0.78	-0.91
Cash	0.52	0.2	0.31	0.39	-0.14	0.11	0.67	0.22	-0.92	-0.43	0.77		0.24	0.34	0.35	-0.16	0.54	0.32	0.66	0.5	-0.16	-0.17	0.64	0.48	0.27	-0.62
Non Current Assets Total	0.91	1.0	0.94	0.92	0.81	0.83	0.74	1.0	0.16	-0.89	0.49	0.24		0.98	-0.11	-0.94	0.89	0.99	0.7	0.65	-0.94	0.82	0.62	0.74	0.49	-0.68
Non Currrent Assets Other	0.91	0.98	0.92	0.89	0.81	0.8	0.76	0.98	0.05	-0.86	0.48	0.34	0.98		-0.19	-0.92	0.89	0.97	0.65	0.6	-0.92	0.78	0.63	0.75	0.37	-0.67
Other Assets	0.17	-0.16	0.09	0.16	-0.53	0.11	0.36	-0.13	-0.42	-0.2	0.55	0.35	-0.11	-0.19		0.2	0.19	-0.01	0.51	0.42	0.2	-0.47	0.5	0.01	0.72	-0.43
Long Term Debt	-0.81	-0.94	-0.86	-0.83	-0.83	-0.76	-0.63	-0.94	-0.23	0.78	-0.32	-0.16	-0.94	-0.92	0.2		-0.79	-0.92	-0.58	-0.44	1.0	-0.84	-0.49	-0.67	-0.32	0.56
Cash And Short Term Investments	1.0	0.85	0.96	0.98	0.47	0.87	0.97	0.88	-0.2	-0.98	0.79	0.54	0.89	0.89	0.19	-0.79		0.94	0.89	0.85	-0.79	0.53	0.85	0.88	0.67	-0.93
Net Receivables	0.95	0.98	0.97	0.96	0.73	0.87	0.82	0.99	0.07	-0.93	0.58	0.32	0.99	0.97	-0.01	-0.92	0.94		0.77	0.72	-0.92	0.75	0.71	0.78	0.57	-0.77
Common Stock Total Equity	0.88	0.64	0.8	0.86	0.19	0.66	0.93	0.68	-0.4	-0.89	0.94	0.66	0.7	0.65	0.51	-0.58	0.89	0.77		0.9	-0.58	0.26	0.87	0.75	0.83	-0.94
Common Stock Shares Outstanding	0.84	0.59	0.8	0.85	0.14	0.73	0.88	0.63	-0.27	-0.9	0.88	0.5	0.65	0.6	0.42	-0.44	0.85	0.72	0.9		-0.44	0.29	0.76	0.82	0.82	-0.94
Long Term Debt Total	-0.81	-0.94	-0.86	-0.83	-0.83	-0.76	-0.63	-0.94	-0.23	0.78	-0.32	-0.16	-0.94	-0.92	0.2	1.0	-0.79	-0.92	-0.58	-0.44		-0.84	-0.49	-0.67	-0.32	0.56
Non Current Liabilities Total	0.56	0.85	0.68	0.62	0.91	0.6	0.29	0.83	0.51	-0.59	0.0	-0.17	0.82	0.78	-0.47	-0.84	0.53	0.75	0.26	0.29	-0.84		0.08	0.54	0.08	-0.27
Capital Surpluse	0.83	0.58	0.73	0.79	0.14	0.68	0.92	0.61	-0.41	-0.77	0.88	0.64	0.62	0.63	0.5	-0.49	0.85	0.71	0.87	0.76	-0.49	0.08		0.57	0.79	-0.86
Inventory	0.88	0.7	0.86	0.88	0.34	0.78	0.85	0.73	-0.2	-0.9	0.68	0.48	0.74	0.75	0.01	-0.67	0.88	0.78	0.75	0.82	-0.67	0.54	0.57		0.46	-0.88
Other Current Assets	0.66	0.43	0.65	0.7	0.0	0.64	0.72	0.48	-0.1	-0.72	0.78	0.27	0.49	0.37	0.72	-0.32	0.67	0.57	0.83	0.82	-0.32	0.08	0.79	0.46		-0.78
Other Stockholder Equity	-0.92	-0.63	-0.85	-0.9	-0.14	-0.79	-0.98	-0.67	0.37	0.93	-0.91	-0.62	-0.68	-0.67	-0.43	0.56	-0.93	-0.77	-0.94	-0.94	0.56	-0.27	-0.86	-0.88	-0.78

Click cells to compare fundamentals

Crinetics Pharmaceuticals Account Relationship Matchups

Crinetics Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	130.4M	183.4M	351.0M	352.2M	635.4M	667.1M
Other Current Liab	2.8M	4.9M	7.5M	17.5M	31.2M	32.7M
Total Current Liabilities	8.3M	10.5M	16.0M	27.7M	43.9M	46.1M
Total Stockholder Equity	(93.8M)	(167.6M)	(275.3M)	(439.2M)	539.1M	566.1M
Net Tangible Assets	117.1M	168.9M	331.9M	316.3M	363.8M	382.0M
Property Plant And Equipment Net	6.5M	5.4M	4.7M	5.0M	57.4M	60.3M
Net Debt	(35.5M)	(89.1M)	(197.6M)	(30.6M)	(3.2M)	(3.3M)
Retained Earnings	(93.8M)	(167.6M)	(275.3M)	(439.2M)	(653.7M)	(621.0M)
Accounts Payable	5.5M	5.6M	8.5M	6.9M	6.5M	4.8M
Cash	40.3M	93.1M	200.7M	32.7M	54.9M	67.8M
Non Current Assets Total	7.0M	6.0M	6.3M	7.0M	61.2M	64.3M
Non Currrent Assets Other	82K	40K	568K	37K	2.0M	2.1M
Other Assets	582K	2.8M	568K	2.0M	1.0	0.95
Cash And Short Term Investments	118.4M	170.9M	333.7M	334.4M	558.6M	586.5M
Net Receivables	1.4M	1.8M	2.0M	2.4M	9.4M	9.8M
Common Stock Shares Outstanding	24.2M	30.4M	38.4M	52.0M	58.1M	33.4M
Liabilities And Stockholders Equity	(80.6M)	(153.1M)	(256.2M)	(403.3M)	635.4M	667.1M
Non Current Liabilities Total	4.9M	4.0M	3.1M	8.1M	52.3M	54.9M
Other Current Assets	4.9M	6.6M	912K	8.3M	6.2M	3.9M
Other Stockholder Equity	(210.9M)	(336.5M)	(607.2M)	(755.5M)	(680.0M)	(646.0M)
Total Liab	13.2M	14.5M	19.1M	35.8M	96.2M	101.1M
Property Plant And Equipment Gross	6.5M	3.2M	8.2M	9.1M	62.5M	65.6M
Total Current Assets	123.3M	177.5M	344.7M	345.2M	574.2M	602.9M
Accumulated Other Comprehensive Income	148K	25K	(382K)	(3.9M)	977K	1.0M
Non Current Liabilities Other	202K	4.8M	4.0M	2K	2.3K	2.2K
Common Stock	210.8M	336.5M	607.6M	759.4M	1.2B	1.3B
Property Plant Equipment	6.5M	5.4M	4.7M	5.0M	5.7M	4.2M
Net Invested Capital	117.1M	168.9M	331.9M	316.3M	539.1M	566.1M
Net Working Capital	115.0M	167.0M	328.7M	317.5M	530.2M	556.7M
Short Term Investments	78.1M	77.8M	133.0M	301.8M	503.7M	528.8M
Capital Stock	210.8M	336.5M	607.6M	759.4M	1.2B	1.3B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Crinetics Capital Surpluse vs Long Term Debt Analysis

Capital Surpluse vs Long Term Debt

Capital Surpluse vs Long Term Debt Correlation Analysis

Correlation Coefficient

Capital Surpluse

Long Term Debt

Crinetics Pharmaceuticals fundamental ratios Correlations

Crinetics Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Crinetics Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Crinetics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Current Liabilities	+ 0.99	Total Assets

Retained Earnings	- 0.99	Total Current Liabilities
Cash And Short Term Investments	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Net Tangible Assets
Retained Earnings	- 0.98	Other Current Liab
Retained Earnings	- 0.98	Total Assets
Other Stockholder Equity	- 0.94	Common Stock Shares Outstanding